董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joan Chypyha | 女 | Director | 57 | 3.08万美元 | 未持股 | 2023-12-15 |
| Frank R. Oakes | 男 | Director | 73 | 5.64万美元 | 5.92 | 2023-12-15 |
| Charles V. Olson | 男 | Director | 66 | 2.81万美元 | 0.10 | 2023-12-15 |
| Sean MacDonald | 男 | Director | 47 | 6.80万美元 | 未持股 | 2023-12-15 |
| Carlo Sistilli | 男 | Board Chair | 67 | 6.78万美元 | 未持股 | 2023-12-15 |
| Pardeep Nijhawan | 男 | Director, Chief Executive Officer and Corporate Secretary | 53 | 54.96万美元 | 未持股 | 2023-12-15 |
| Joan Chypyha | 女 | Director | 57 | 未披露 | 未持股 | 2023-12-15 |
| Patrick Marshall | 男 | Director | 52 | 2.92万美元 | 未持股 | 2023-12-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Brooks | 男 | President | 45 | 48.88万美元 | 未持股 | 2023-12-15 |
| Pardeep Nijhawan | 男 | Director, Chief Executive Officer and Corporate Secretary | 53 | 54.96万美元 | 未持股 | 2023-12-15 |
| Stephen Lemieux | 男 | Chief Financial Officer | 48 | 15.59万美元 | 未持股 | 2023-12-15 |
董事简历
中英对照 | 中文 | 英文- Joan Chypyha
-
Joan Chypyha，此前，她曾是Rhei Pharmaceuticals Ltd.的首席开发官；Barrier Therapeutics Inc.的公司发展副总裁；Barrier Therapeutics Canada Inc.的总经理； Alto Pharmaceuticals Ltd.的创会死人。她也在Hoffman-La Roche任职16年并不断被提拔，包括也为透析和部分肠外营养部门主管和皮肤医学的业务部门主管。担任该职位时，她负责代表青春痘特效药等品牌专业销售人员的管理。她获得University of Toronto的学士学位和Queen’s University的工商管理硕士学位。
Joan Chypyha,has more than 30 years of experience in the pharmaceutical industry including executive and operational positions in business development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company focused on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previously served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman-La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from August 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Industry Association, from 2015 to 2023, and is a Co-Chair of DiTiDE (Dermatology Industry Taskforce on Inclusiveness, Diversity & Equity), a group she co-founded in 2020. She has also previously served on boards of other non-profits and business organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Business Administration from Queen's University. - Joan Chypyha，此前，她曾是Rhei Pharmaceuticals Ltd.的首席开发官；Barrier Therapeutics Inc.的公司发展副总裁；Barrier Therapeutics Canada Inc.的总经理； Alto Pharmaceuticals Ltd.的创会死人。她也在Hoffman-La Roche任职16年并不断被提拔，包括也为透析和部分肠外营养部门主管和皮肤医学的业务部门主管。担任该职位时，她负责代表青春痘特效药等品牌专业销售人员的管理。她获得University of Toronto的学士学位和Queen’s University的工商管理硕士学位。
- Joan Chypyha,has more than 30 years of experience in the pharmaceutical industry including executive and operational positions in business development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company focused on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previously served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman-La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from August 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Industry Association, from 2015 to 2023, and is a Co-Chair of DiTiDE (Dermatology Industry Taskforce on Inclusiveness, Diversity & Equity), a group she co-founded in 2020. She has also previously served on boards of other non-profits and business organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Business Administration from Queen's University.
- Frank R. Oakes
-
Frank R. Oakes，拥有40多年的行政领导经验。他自2010年4月起担任公司董事，并担任董事会主席至2019年6月。从1999年到2019年，他还担任公司传统运营子公司的总裁兼首席执行官，该子公司是他创立的。在创立Stellar Biotechnologies公司之前，他是鲍鱼农场公司的首席执行官，在那里他带领公司完成了研发、资本化和商业化发展阶段，成为当时美国最大的鲍鱼生产商。Oakes先生在世界各地进行过咨询和演讲。他在加州州立理工大学圣路易斯奥比斯波分校获得学士学位，并毕业于洛杉矶区域技术联盟大学的管理课程。Oakes担任董事会成员的资格包括他在建立公司和管理团队以及领导一家美国和加拿大上市的生命科学公司方面的丰富运营经验。
Frank R. Oakes,has more than 40 years of executive leadership experience. He has been a member of Edesa Biotech, Inc. board of directors since April 2010 and served as the Chairman of the Board until June 2019. From 1999 to 2019, he also served as the President and Chief Executive Officer of Edesa Biotech, Inc. legacy operating subsidiary, which he founded. Prior to founding Stellar Biotechnologies, Inc., he was the Chief Executive Officer of The Abalone Farm, Inc., where he led the company through the research and development, capitalization, and commercialization phases of development to become the largest abalone producer in the United States at the time. Mr. Oakes has consulted and lectured around the world. He received his BS degree from California State Polytechnic University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance University's management program. - Frank R. Oakes，拥有40多年的行政领导经验。他自2010年4月起担任公司董事，并担任董事会主席至2019年6月。从1999年到2019年，他还担任公司传统运营子公司的总裁兼首席执行官，该子公司是他创立的。在创立Stellar Biotechnologies公司之前，他是鲍鱼农场公司的首席执行官，在那里他带领公司完成了研发、资本化和商业化发展阶段，成为当时美国最大的鲍鱼生产商。Oakes先生在世界各地进行过咨询和演讲。他在加州州立理工大学圣路易斯奥比斯波分校获得学士学位，并毕业于洛杉矶区域技术联盟大学的管理课程。Oakes担任董事会成员的资格包括他在建立公司和管理团队以及领导一家美国和加拿大上市的生命科学公司方面的丰富运营经验。
- Frank R. Oakes,has more than 40 years of executive leadership experience. He has been a member of Edesa Biotech, Inc. board of directors since April 2010 and served as the Chairman of the Board until June 2019. From 1999 to 2019, he also served as the President and Chief Executive Officer of Edesa Biotech, Inc. legacy operating subsidiary, which he founded. Prior to founding Stellar Biotechnologies, Inc., he was the Chief Executive Officer of The Abalone Farm, Inc., where he led the company through the research and development, capitalization, and commercialization phases of development to become the largest abalone producer in the United States at the time. Mr. Oakes has consulted and lectured around the world. He received his BS degree from California State Polytechnic University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance University's management program.
- Charles V. Olson
-
CharlesV.Olson自2016年12月起担任Stellar的董事，自2014年6月起担任我们的科学顾问委员会成员，并担任薪酬委员会主席。自2017年9月以来，他一直任职于Applied Molecular TransportInc.，担任生物制剂Vice President。2006年以来，他也一直担任Compass Biotechnology LLC的首席生物技术顾问。Olson博士此前于2010年4月至2017年8月在临床阶段生物制药公司NGM Biopharmaceuticals Inc.，专注于生物仿制药的公司Coherus Biosciences Inc.，药物开发公司NexBio Inc.，生物技术公司Cell Genesys，Inc.担任高级和执行管理职位，Biomarin Pharmaceuticals，Inc.，一家为严重和危及生命的罕见疾病开发和商业化疗法的公司，以及OnyxPharmaceuticals，Inc.，一家生物制药公司。研究生毕业后，Olson博士是Kaiser Hospitals的研究科学家，随后分别在Genentech和Bayer担任科学家和高级科学家职位。他持有Westmont College的生物学和化学学士学位、加州大学圣巴巴拉分校（the University of California at Santa Barbara）的化学硕士学位和工商管理硕士学位。在生物化学。Olson博士在生物制药行业拥有丰富的科学、制造运营、工艺开发和高级管理经验。
Charles V. Olson,is a CMC consultant with more than 40 years of biotech experience. From September 2021 to April 2023 he was Chief Operating Officer at Dendreon Corporation, where he was responsible for the commercial manufacturing of Provenge, a commercial cell-based product for prostate cancer, overseeing multiple sites and several hundred employees. From September 2017 to August 2021, he was a senior Vice President of Operations at Applied Molecular Transport. From April 2010 to August 2017, Dr. Olson held various leadership roles at Anthera Pharmaceuticals Inc., including Chief Technology Officer. He has also been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previously held senior and executive management positions at NGM Biopharmaceuticals Inc., Coherus BioSciences Inc., Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx Pharmaceuticals, Inc. From December 2016 to June 2019, Dr. Olson served on the board of directors of Edesa Biotech, Inc. (then operating as Stellar Biotechnologies, Inc.), having previously served on Stellar's scientific advisory board. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, followed by Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from Westmont College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry. - CharlesV.Olson自2016年12月起担任Stellar的董事，自2014年6月起担任我们的科学顾问委员会成员，并担任薪酬委员会主席。自2017年9月以来，他一直任职于Applied Molecular TransportInc.，担任生物制剂Vice President。2006年以来，他也一直担任Compass Biotechnology LLC的首席生物技术顾问。Olson博士此前于2010年4月至2017年8月在临床阶段生物制药公司NGM Biopharmaceuticals Inc.，专注于生物仿制药的公司Coherus Biosciences Inc.，药物开发公司NexBio Inc.，生物技术公司Cell Genesys，Inc.担任高级和执行管理职位，Biomarin Pharmaceuticals，Inc.，一家为严重和危及生命的罕见疾病开发和商业化疗法的公司，以及OnyxPharmaceuticals，Inc.，一家生物制药公司。研究生毕业后，Olson博士是Kaiser Hospitals的研究科学家，随后分别在Genentech和Bayer担任科学家和高级科学家职位。他持有Westmont College的生物学和化学学士学位、加州大学圣巴巴拉分校（the University of California at Santa Barbara）的化学硕士学位和工商管理硕士学位。在生物化学。Olson博士在生物制药行业拥有丰富的科学、制造运营、工艺开发和高级管理经验。
- Charles V. Olson,is a CMC consultant with more than 40 years of biotech experience. From September 2021 to April 2023 he was Chief Operating Officer at Dendreon Corporation, where he was responsible for the commercial manufacturing of Provenge, a commercial cell-based product for prostate cancer, overseeing multiple sites and several hundred employees. From September 2017 to August 2021, he was a senior Vice President of Operations at Applied Molecular Transport. From April 2010 to August 2017, Dr. Olson held various leadership roles at Anthera Pharmaceuticals Inc., including Chief Technology Officer. He has also been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previously held senior and executive management positions at NGM Biopharmaceuticals Inc., Coherus BioSciences Inc., Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx Pharmaceuticals, Inc. From December 2016 to June 2019, Dr. Olson served on the board of directors of Edesa Biotech, Inc. (then operating as Stellar Biotechnologies, Inc.), having previously served on Stellar's scientific advisory board. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, followed by Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from Westmont College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry.
- Sean MacDonald
-
Sean MacDonald自2019年6月起担任董事会主席，此前自2017年9月起担任公司主要运营子公司Edesa Biotech Research，Inc.的董事。MacDonald先生目前是Cosmo Pharmaceuticals NV的业务开发主管，这是一家专注于欧洲胃肠病学的制药公司，他自2019年4月以来一直担任该职位，他还担任Corbin Therapeutics的首席执行官，Corbin Therapeutics是一家总部位于蒙特利尔的生物技术公司，专注于治疗神经炎，他自2018年10月起担任该职位。从2012年10月至2018年10月，麦克唐纳先生在Pharmascience Inc.（加拿大最大的制药公司之一）担任过各种运营和执行领导职务，包括业务发展和企业发展的Vice President。他在渥太华大学（University of Ottawa）获得分子生物学学士学位和工商管理硕士学位。
Sean MacDonald,has been a member of Edesa Biotech, Inc. Board since June 2019, and served as Chairman of the Board from June 2019 until May 2023. He previously served on the board of Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, from September 2017 to June 2019. In his career, he has led and closed multiple licensing transactions, financings, acquisitions and divestments, and led corporate strategy for several pharmaceutical and biotechnology companies. Mr. MacDonald is currently an advisor to investors and biotechnology companies, including Domain Therapeutics Inc. and Raya Therapeutic Inc., a role he has held since April 2022. From August 2021 to April 2022, he was the Chief Business Officer of iOnctura SA, a Swiss clinical-stage oncology company. From April 2019 to August 2021, he was the Head of Business Development for Cosmo Pharmaceuticals NV, a European gastroenterology focused pharmaceutical company; and from October 2018 to August 2021 he was the chief executive of Corbin Therapeutics, a Montreal-based biotech company focused on treating neuroinflammation. Mr. MacDonald held various operational and executive leadership roles from October 2012 to October 2018 at Pharmascience Inc., one of Canada's largest pharmaceutical companies, including Vice President of Business Development and Corporate Development. He received his BSc in Molecular Biology and MBA from the University of Ottawa. - Sean MacDonald自2019年6月起担任董事会主席，此前自2017年9月起担任公司主要运营子公司Edesa Biotech Research，Inc.的董事。MacDonald先生目前是Cosmo Pharmaceuticals NV的业务开发主管，这是一家专注于欧洲胃肠病学的制药公司，他自2019年4月以来一直担任该职位，他还担任Corbin Therapeutics的首席执行官，Corbin Therapeutics是一家总部位于蒙特利尔的生物技术公司，专注于治疗神经炎，他自2018年10月起担任该职位。从2012年10月至2018年10月，麦克唐纳先生在Pharmascience Inc.（加拿大最大的制药公司之一）担任过各种运营和执行领导职务，包括业务发展和企业发展的Vice President。他在渥太华大学（University of Ottawa）获得分子生物学学士学位和工商管理硕士学位。
- Sean MacDonald,has been a member of Edesa Biotech, Inc. Board since June 2019, and served as Chairman of the Board from June 2019 until May 2023. He previously served on the board of Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, from September 2017 to June 2019. In his career, he has led and closed multiple licensing transactions, financings, acquisitions and divestments, and led corporate strategy for several pharmaceutical and biotechnology companies. Mr. MacDonald is currently an advisor to investors and biotechnology companies, including Domain Therapeutics Inc. and Raya Therapeutic Inc., a role he has held since April 2022. From August 2021 to April 2022, he was the Chief Business Officer of iOnctura SA, a Swiss clinical-stage oncology company. From April 2019 to August 2021, he was the Head of Business Development for Cosmo Pharmaceuticals NV, a European gastroenterology focused pharmaceutical company; and from October 2018 to August 2021 he was the chief executive of Corbin Therapeutics, a Montreal-based biotech company focused on treating neuroinflammation. Mr. MacDonald held various operational and executive leadership roles from October 2012 to October 2018 at Pharmascience Inc., one of Canada's largest pharmaceutical companies, including Vice President of Business Development and Corporate Development. He received his BSc in Molecular Biology and MBA from the University of Ottawa.
- Carlo Sistilli
-
Carlo Sistilli拥有超过35年的财务经验，并在其职业生涯中担任过多个会计和财务执行职位。他自2019年6月以来一直担任我们的董事会成员，此前曾担任公司的主要运营子公司Edesa Biotech Research，Inc.的董事会观察员（2017年9月以来）。Sistilli先生自2003年3月起担任Arista Homes的首席财务官。在Arista之前，Sistilli先生是一家汽车领域的互联网初创公司的创始人并担任首席财务官和董事会成员，并在将该公司在阿尔伯塔省风险投资交易所上市方面发挥了关键作用。在其职业生涯早期，Sistilli先生是一家主要区域信托公司的财务总监和高级管理团队成员，Sistilli先生帮助将其出售给Manulife Financial。自2021年1月以来，他一直担任Aleafia Health Inc.的董事会和审计委员会成员。除了他的职业生涯，Sistilli先生是Mother of Mercy Center的官员和董事会成员。Sistilli先生持有York University文学学士学位，主修经济学，注册管理会计师指定和特许专业会计师指定。
Carlo Sistilli,has more than 35 years of financial experience and has held a variety of executive positions in accounting and finance during his career. He has been a member of Edesa Biotech, Inc. board of directors since June 2019, having previously served as a board observer of Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since September 2017. Mr. Sistilli has served as the Chief Financial Officer of Arista Homes since March 2003 to present. Prior to Arista, Mr. Sistilli was a founder and served as CFO and a board member of an Internet start-up company in the automotive sector, and played a key role in taking the company public on the Alberta Ventures Exchange. Earlier in his career, Mr. Sistilli was the Controller and a member of the senior management team of a major regional trust company, which Mr. Sistilli helped sell to Manulife Financial. Since January 2021, he has served on the board of directors and audit committee of Aleafia Health Inc. In addition to his professional career, Mr. Sistilli is an officer and a member of the board of directors of Mother of Mercy Centre. Mr. Sistilli holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation. - Carlo Sistilli拥有超过35年的财务经验，并在其职业生涯中担任过多个会计和财务执行职位。他自2019年6月以来一直担任我们的董事会成员，此前曾担任公司的主要运营子公司Edesa Biotech Research，Inc.的董事会观察员（2017年9月以来）。Sistilli先生自2003年3月起担任Arista Homes的首席财务官。在Arista之前，Sistilli先生是一家汽车领域的互联网初创公司的创始人并担任首席财务官和董事会成员，并在将该公司在阿尔伯塔省风险投资交易所上市方面发挥了关键作用。在其职业生涯早期，Sistilli先生是一家主要区域信托公司的财务总监和高级管理团队成员，Sistilli先生帮助将其出售给Manulife Financial。自2021年1月以来，他一直担任Aleafia Health Inc.的董事会和审计委员会成员。除了他的职业生涯，Sistilli先生是Mother of Mercy Center的官员和董事会成员。Sistilli先生持有York University文学学士学位，主修经济学，注册管理会计师指定和特许专业会计师指定。
- Carlo Sistilli,has more than 35 years of financial experience and has held a variety of executive positions in accounting and finance during his career. He has been a member of Edesa Biotech, Inc. board of directors since June 2019, having previously served as a board observer of Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since September 2017. Mr. Sistilli has served as the Chief Financial Officer of Arista Homes since March 2003 to present. Prior to Arista, Mr. Sistilli was a founder and served as CFO and a board member of an Internet start-up company in the automotive sector, and played a key role in taking the company public on the Alberta Ventures Exchange. Earlier in his career, Mr. Sistilli was the Controller and a member of the senior management team of a major regional trust company, which Mr. Sistilli helped sell to Manulife Financial. Since January 2021, he has served on the board of directors and audit committee of Aleafia Health Inc. In addition to his professional career, Mr. Sistilli is an officer and a member of the board of directors of Mother of Mercy Centre. Mr. Sistilli holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation.
- Pardeep Nijhawan
-
Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
Pardeep Nijhawan,has served as Edesa Biotech, Inc. Chief Executive Officer, Corporate Secretary and a member of Edesa Biotech, Inc. board of directors since June 2019, having previously founded and led Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross-functional leadership roles in finance, marketing, corporate strategy and business development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian-based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the Board of Digestive Health Clinic. Since January 2021, he has served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic. - Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
- Pardeep Nijhawan,has served as Edesa Biotech, Inc. Chief Executive Officer, Corporate Secretary and a member of Edesa Biotech, Inc. board of directors since June 2019, having previously founded and led Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross-functional leadership roles in finance, marketing, corporate strategy and business development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian-based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the Board of Digestive Health Clinic. Since January 2021, he has served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.
- Joan Chypyha
-
Joan Chypyha，在制药行业拥有30多年的经验，包括业务发展、销售和市场营销以及一般管理方面的行政和运营职位。她是奥拓医药有限公司的总裁，这是一家专注于皮肤病学、女性健康和老年护理的专业制药公司，她于2009年创立了该公司。奥拓也是Pepper and Pink Inc.的主要股东，Pepper and Pink Inc.是一家为加拿大主要零售商提供品牌和自有品牌个人护理产品的制造商。2015年7月至2017年6月，她担任Cipher制药公司总裁，此前曾担任市场和销售副总裁。Chypyha女士的职业生涯还包括Rhei Pharmaceuticals Ltd.和Barrier Therapeutics Canada，Inc.的高管职位，此前她在Hoffman-La Roche工作了16年，在那里她逐渐担任高级职位。自2018年2月起，她担任Ovation Science Inc.的董事和审计委员会成员，Ovation Science Inc.是一家开发外用和透皮消费品的研发公司。她是Up Cannabis Inc的前任顾问委员会成员（2017年8月至2019年1月）。Chypyha女士目前担任加拿大皮肤病学行业协会主席，2015年至2023年，是她于2020年共同创立的组织DiTIDE（皮肤病学行业包容性、多样性和公平工作组）的联合主席。她此前还曾在其他非营利组织和商业组织的董事会任职，包括加拿大医疗保健许可协会。Chypyha女士获得了多伦多大学的学士学位和女王大学的工商管理硕士学位。
Joan Chypyha,has more than 30 years of experience in the pharmaceutical industry including executive and operational positions in business development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company focused on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previously served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman-La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from August 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Industry Association, from 2015 to 2023, and is a Co-Chair of DiTiDE (Dermatology Industry Taskforce on Inclusiveness, Diversity & Equity), a group she co-founded in 2020. She has also previously served on boards of other non-profits and business organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Business Administration from Queen's University. - Joan Chypyha，在制药行业拥有30多年的经验，包括业务发展、销售和市场营销以及一般管理方面的行政和运营职位。她是奥拓医药有限公司的总裁，这是一家专注于皮肤病学、女性健康和老年护理的专业制药公司，她于2009年创立了该公司。奥拓也是Pepper and Pink Inc.的主要股东，Pepper and Pink Inc.是一家为加拿大主要零售商提供品牌和自有品牌个人护理产品的制造商。2015年7月至2017年6月，她担任Cipher制药公司总裁，此前曾担任市场和销售副总裁。Chypyha女士的职业生涯还包括Rhei Pharmaceuticals Ltd.和Barrier Therapeutics Canada，Inc.的高管职位，此前她在Hoffman-La Roche工作了16年，在那里她逐渐担任高级职位。自2018年2月起，她担任Ovation Science Inc.的董事和审计委员会成员，Ovation Science Inc.是一家开发外用和透皮消费品的研发公司。她是Up Cannabis Inc的前任顾问委员会成员（2017年8月至2019年1月）。Chypyha女士目前担任加拿大皮肤病学行业协会主席，2015年至2023年，是她于2020年共同创立的组织DiTIDE（皮肤病学行业包容性、多样性和公平工作组）的联合主席。她此前还曾在其他非营利组织和商业组织的董事会任职，包括加拿大医疗保健许可协会。Chypyha女士获得了多伦多大学的学士学位和女王大学的工商管理硕士学位。
- Joan Chypyha,has more than 30 years of experience in the pharmaceutical industry including executive and operational positions in business development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company focused on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previously served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman-La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from August 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Industry Association, from 2015 to 2023, and is a Co-Chair of DiTiDE (Dermatology Industry Taskforce on Inclusiveness, Diversity & Equity), a group she co-founded in 2020. She has also previously served on boards of other non-profits and business organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Business Administration from Queen's University.
- Patrick Marshall
-
Patrick Marshall，在筹集资金、构建和推出新产品和服务、制定战略和完成并购以支持私营和上市公司的增长方面拥有超过20年的经验。自2010年以来，他一直担任VRG Capital的董事总经理，此前自2000年以来曾在该公司的多家投资组合公司担任多个执行职务，包括Wheels Group Inc.，一家于2015年被Radiant物流公司收购的北美第三方物流公司，以及Thomas International Ltd.，一家于2018年被Palamon Capital Partners收购的心理测量和能力倾向测试的全球供应商。Marshall先生目前担任Adrem Brands Inc.的总裁兼董事会成员，该公司是一家加拿大私营公司，专注于非处方药和营养补充剂市场，他自2016年1月以来一直担任该职位。在2000年之前，他担任过各种国际企业和非政府组织的筹款、业务发展和战略角色。Marshall先生是Together Project的联合创始人和董事会成员（自2016年起），也是Lakefield College School的受托人（自2012年起）。他在皇后大学获得社会学文学学士学位，在埃克塞特大学获得工商管理硕士学位。
Patrick Marshall,has more than 20 years of experience raising capital, building and launching new products and services, developing strategy and completing mergers and acquisitions to support growth in private and public companies. Since 2010 he has been a managing director at VRG Capital, having previously held various executive roles in several of the firm's portfolio companies since 2000, including Wheels Group Inc., a North American third-party logistics company acquired by Radiant Logistics, Inc. in 2015, and Thomas International Ltd., a global provider of psychometric and aptitude tests acquired by Palamon Capital Partners in 2018. Mr. Marshall currently serves as President and board member of Adrem Brands Inc., a privately held Canadian company focused on the over-the-counter and nutritional supplements markets, a position he has held since January 2016. Prior to 2000, he held fundraising, business development and strategy roles for various international enterprises and non-governmental organizations. Mr. Marshall is a cofounder and board member of Together Project (since 2016) and a trustee of Lakefield College School (since 2012). He received his Bachelor of Arts in Sociology from Queen's University and Master of Business Administration from the University of Exeter. - Patrick Marshall，在筹集资金、构建和推出新产品和服务、制定战略和完成并购以支持私营和上市公司的增长方面拥有超过20年的经验。自2010年以来，他一直担任VRG Capital的董事总经理，此前自2000年以来曾在该公司的多家投资组合公司担任多个执行职务，包括Wheels Group Inc.，一家于2015年被Radiant物流公司收购的北美第三方物流公司，以及Thomas International Ltd.，一家于2018年被Palamon Capital Partners收购的心理测量和能力倾向测试的全球供应商。Marshall先生目前担任Adrem Brands Inc.的总裁兼董事会成员，该公司是一家加拿大私营公司，专注于非处方药和营养补充剂市场，他自2016年1月以来一直担任该职位。在2000年之前，他担任过各种国际企业和非政府组织的筹款、业务发展和战略角色。Marshall先生是Together Project的联合创始人和董事会成员（自2016年起），也是Lakefield College School的受托人（自2012年起）。他在皇后大学获得社会学文学学士学位，在埃克塞特大学获得工商管理硕士学位。
- Patrick Marshall,has more than 20 years of experience raising capital, building and launching new products and services, developing strategy and completing mergers and acquisitions to support growth in private and public companies. Since 2010 he has been a managing director at VRG Capital, having previously held various executive roles in several of the firm's portfolio companies since 2000, including Wheels Group Inc., a North American third-party logistics company acquired by Radiant Logistics, Inc. in 2015, and Thomas International Ltd., a global provider of psychometric and aptitude tests acquired by Palamon Capital Partners in 2018. Mr. Marshall currently serves as President and board member of Adrem Brands Inc., a privately held Canadian company focused on the over-the-counter and nutritional supplements markets, a position he has held since January 2016. Prior to 2000, he held fundraising, business development and strategy roles for various international enterprises and non-governmental organizations. Mr. Marshall is a cofounder and board member of Together Project (since 2016) and a trustee of Lakefield College School (since 2012). He received his Bachelor of Arts in Sociology from Queen's University and Master of Business Administration from the University of Exeter.
高管简历
中英对照 | 中文 | 英文- Michael Brooks
Michael Brooks于2019年6月被任命为Edesa的总裁，自2015年1月起担任公司主要运营子公司Edesa Biotech Research，Inc.的企业发展和战略Vice President。在加入Edesa之前，Brooks博士于2010年至2015年在Cipher Pharmaceuticals Inc.担任职责递增的职位，最近担任该公司的业务开发总监。加入Cipher之前，Brooks博士是多伦多大学（University of Toronto）的博士后。Brooks博士拥有荣誉学士学位。the University of Toronto微生物学学位和分子遗传学博士学位。Brooks博士在罗特曼管理学院（Rotman School of Management）获得工商管理硕士学位，在那里他是加拿大健康研究所CIHR Science to Business学者。
Michael Brooks,was appointed President of Edesa in June 2019, having served as Vice President of Corporate Development and Strategy for Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Prior to joining Edesa, Dr. Brooks held positions of increasing responsibility at Cipher Pharmaceuticals Inc from 2010 to 2015 and served most recently as the company's Director of Business Development. Prior to joining Cipher, Dr. Brooks was a Postdoctoral fellow at the University of Toronto. Dr. Brooks holds a Hons B.Sc. degree in Microbiology and a PhD in Molecular Genetics from the University of Toronto. Dr. Brooks received his MBA degree from the Rotman School of Management where he was a Canadian Institute for Health Research (CIHR) Science-to- Business Scholar.- Michael Brooks于2019年6月被任命为Edesa的总裁，自2015年1月起担任公司主要运营子公司Edesa Biotech Research，Inc.的企业发展和战略Vice President。在加入Edesa之前，Brooks博士于2010年至2015年在Cipher Pharmaceuticals Inc.担任职责递增的职位，最近担任该公司的业务开发总监。加入Cipher之前，Brooks博士是多伦多大学（University of Toronto）的博士后。Brooks博士拥有荣誉学士学位。the University of Toronto微生物学学位和分子遗传学博士学位。Brooks博士在罗特曼管理学院（Rotman School of Management）获得工商管理硕士学位，在那里他是加拿大健康研究所CIHR Science to Business学者。
- Michael Brooks,was appointed President of Edesa in June 2019, having served as Vice President of Corporate Development and Strategy for Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Prior to joining Edesa, Dr. Brooks held positions of increasing responsibility at Cipher Pharmaceuticals Inc from 2010 to 2015 and served most recently as the company's Director of Business Development. Prior to joining Cipher, Dr. Brooks was a Postdoctoral fellow at the University of Toronto. Dr. Brooks holds a Hons B.Sc. degree in Microbiology and a PhD in Molecular Genetics from the University of Toronto. Dr. Brooks received his MBA degree from the Rotman School of Management where he was a Canadian Institute for Health Research (CIHR) Science-to- Business Scholar.
- Pardeep Nijhawan
Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
Pardeep Nijhawan,has served as Edesa Biotech, Inc. Chief Executive Officer, Corporate Secretary and a member of Edesa Biotech, Inc. board of directors since June 2019, having previously founded and led Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross-functional leadership roles in finance, marketing, corporate strategy and business development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian-based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the Board of Digestive Health Clinic. Since January 2021, he has served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.- Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
- Pardeep Nijhawan,has served as Edesa Biotech, Inc. Chief Executive Officer, Corporate Secretary and a member of Edesa Biotech, Inc. board of directors since June 2019, having previously founded and led Edesa Biotech, Inc. principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross-functional leadership roles in finance, marketing, corporate strategy and business development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian-based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the Board of Digestive Health Clinic. Since January 2021, he has served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.
- Stephen Lemieux
Stephen Lemieux，2023年7月被任命为首席财务官。他是医疗保健和生物制药领域的资深人士，在财务规划和分析、许可和并购方面拥有超过20年的经验。在加入公司之前，Lemieux先生曾在医疗保健和生物制药生物技术公司担任高级财务领导职务，在那里他指导财务战略、优化资本结构并支持重大的公司交易和销售增长。2021年7月至2023年6月，Lemieux先生担任Titan Medical Inc.的首席财务官，并于2019年4月至2021年7月担任NeuPath Health的首席财务官兼秘书。此前，他于2016年9月至2019年3月担任Cipher制药（TSX：CPH）的首席财务官兼秘书，并在任职期间于2016年11月至2017年4月担任临时首席执行官。在加入Cipher之前，他是Nuvo Pharmaceuticals和Crescita Therapeutics的首席财务官。Lemieux先生是一名特许专业会计师，拥有多伦多大学管理和专业会计硕士学位。
Stephen Lemieux,was appointed Chief Financial Officer in July 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions. Prior to joining the Company, Mr. Lemieux held senior financial leadership positions at healthcare and biopharmaceutical biotechnology companies, where he guided financial strategies, optimized capital structures and supported significant corporate transactions and sales growth. From July 2021 until June 2023, Mr. Lemieux served as CFO of Titan Medical Inc., and from April 2019 to July 2021 as CFO and Secretary of NeuPath Health. Previously, he was the CFO and Secretary of Cipher Pharmaceuticals (TSX: CPH) from September 2016 to March 2019 and during his tenure served as Interim-CEO from November 2016 to April 2017. Prior to Cipher, he was CFO at Nuvo Pharmaceuticals and Crescita Therapeutics. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.- Stephen Lemieux，2023年7月被任命为首席财务官。他是医疗保健和生物制药领域的资深人士，在财务规划和分析、许可和并购方面拥有超过20年的经验。在加入公司之前，Lemieux先生曾在医疗保健和生物制药生物技术公司担任高级财务领导职务，在那里他指导财务战略、优化资本结构并支持重大的公司交易和销售增长。2021年7月至2023年6月，Lemieux先生担任Titan Medical Inc.的首席财务官，并于2019年4月至2021年7月担任NeuPath Health的首席财务官兼秘书。此前，他于2016年9月至2019年3月担任Cipher制药（TSX：CPH）的首席财务官兼秘书，并在任职期间于2016年11月至2017年4月担任临时首席执行官。在加入Cipher之前，他是Nuvo Pharmaceuticals和Crescita Therapeutics的首席财务官。Lemieux先生是一名特许专业会计师，拥有多伦多大学管理和专业会计硕士学位。
- Stephen Lemieux,was appointed Chief Financial Officer in July 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions. Prior to joining the Company, Mr. Lemieux held senior financial leadership positions at healthcare and biopharmaceutical biotechnology companies, where he guided financial strategies, optimized capital structures and supported significant corporate transactions and sales growth. From July 2021 until June 2023, Mr. Lemieux served as CFO of Titan Medical Inc., and from April 2019 to July 2021 as CFO and Secretary of NeuPath Health. Previously, he was the CFO and Secretary of Cipher Pharmaceuticals (TSX: CPH) from September 2016 to March 2019 and during his tenure served as Interim-CEO from November 2016 to April 2017. Prior to Cipher, he was CFO at Nuvo Pharmaceuticals and Crescita Therapeutics. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.